EUVIMEDEUVIMED entdecken
Crossref

Long-Term Quality of Life, Cognitive Function, and Symptom Burden Among Chimeric Antigen Receptor T-Cell Recipients and Associated Cytokine Release Syndrome and Neurotoxicity

Lucy Andersen iD, Ryan J Quinn, Heather Difilippo, Alfred L Garfall, David L Porter, Salimah H Meghani iD, Jie Deng

JCO Oncology Practice · 2026-01 · 22 (1) · 131-140

DOI: 10.1200/op-24-00823 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Oncology Practice, 2026-01. Verfasst von Lucy Andersen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Biobehavioral Health Sciences, School of Nursing, University of Pennsylvania, Philadelphia, PA. Hauptthemen laut MEDLINE: Quality of Life, Cytokine Release Syndrome, Neurotoxicity Syndromes, Immunotherapy, Adoptive. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Immediate side effects after chimeric antigen receptor (CAR) T-cell therapy are well documented and include cytokine release syndrome (CRS) and immune effector-cell–associated neurotoxicity (ICANS). However, long-term patient-reported outcomes are understudied. Using a social determinants of health (SDoH) framework, we described the long-term health-related quality of life (HRQoL), cognitive function, and symptom burden of patients in sustained remission after CAR T-cell therapy and examined the relationship between acute CRS and ICANS and long-term cognitive function and symptom burden. METHODS This cross-sectional study included adults in remission after CAR T-cell therapy for multiple myeloma or B-cell lymphoma who were within 1-5 years post-treatment. We used bivariate analyses to measure associations between clinical and SDoH variables and long-term outcomes and linear regression to examine the relationship between ICANS and CRS toxicity and longer-term outcomes. RESULTS Participants (n = 58) were a median of 67 years of age (22-88), 72% had lymphoma, 28% had multiple myeloma, and they were a median of 2 years (1-4.7) post-CAR T-cell infusion. Most of the participants reported good HRQoL. Over one third of participants reported mild-to-moderate impairment in physical function, social roles and activities, or pain domains. Higher income and employment were significantly associated with better physical HRQoL ( P < .05). Participants reported low symptom burden, with fatigue most commonly reported. Neither CRS nor ICANS toxicity predicted long-term cognitive function or symptom burden. CONCLUSION Patients in long-term remission after CAR T-cell therapy have good HRQoL and cognitive function with minimal symptom burden. Importantly, there was no relationship between CRS and ICANS and long-term symptom burden or cognitive function. Results support the long-term clinical benefit of CAR T-cell therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Quality of LifeCytokine Release SyndromeNeurotoxicity SyndromesImmunotherapy, AdoptiveCognitionReceptors, Chimeric AntigenHumansMaleFemaleMiddle AgedAgedAdultCross-Sectional StudiesAged, 80 and overYoung AdultSymptom Burden

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Biobehavioral Health Sciences, School of Nursing, University of Pennsylvania, Philadelphia, PA.
  • Johnson and Johnson Innovative Medicine, Raritan, NJ.
  • Cell Therapy and Transplant Program, Abramson Cancer Center and Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  • Division of Hematology and Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA.

ORCID-Profile: Lucy Andersen, Salimah H Meghani

Zitieren

APA

Andersen, L., Quinn, R. J., Difilippo, H., Garfall, A. L., Porter, D. L., Meghani, S. H., & Deng, J. (2026). Long-Term Quality of Life, Cognitive Function, and Symptom Burden Among Chimeric Antigen Receptor T-Cell Recipients and Associated Cytokine Release Syndrome and Neurotoxicity. JCO Oncology Practice, 22(1), 131-140. https://doi.org/10.1200/op-24-00823

Vancouver

Andersen L, Quinn RJ, Difilippo H, Garfall AL, Porter DL, Meghani SH, et al. Long-Term Quality of Life, Cognitive Function, and Symptom Burden Among Chimeric Antigen Receptor T-Cell Recipients and Associated Cytokine Release Syndrome and Neurotoxicity. JCO Oncology Practice. 2026;22(1):131-140. doi:10.1200/op-24-00823

BibTeX
@article{Andersen2026,
  author = {Andersen, Lucy and Quinn, Ryan J and Difilippo, Heather and Garfall, Alfred L and Porter, David L and Meghani, Salimah H and Deng, Jie},
  title = {Long-Term Quality of Life, Cognitive Function, and Symptom Burden Among Chimeric Antigen Receptor T-Cell Recipients and Associated Cytokine Release Syndrome and Neurotoxicity},
  journal = {JCO Oncology Practice},
  year = {2026},
  volume = {22},
  number = {1},
  pages = {131--140},
  doi = {10.1200/op-24-00823}
}
Kostenlos starten →